Anthony Doyle

All filings by Anthony Doyle on record concern Biocryst Pharmaceuticals Inc, in the capacity of finance chief. The record holds 13 filings, for trades running from 11 August 2020 to 19 December 2024.

On the open market, the record shows 3 purchases worth €766k and 1 sale worth €58k. On balance, insiders were net buyers of €708k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 9 share grants. 2024 to date brings 1 purchase and no sales.

In size, the median ticket on the buying side is €188k. 2 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.

The latest filing, published on 23 December 2024, reports a share grant in Biocryst Pharmaceuticals Inc. The last purchase on record was published on 15 May 2024, which is 908 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.